留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

选择性雌激素受体调节剂研究现状

丁浩 杨帆 蔡艺 柴晓云 吴秋业

丁浩, 杨帆, 蔡艺, 柴晓云, 吴秋业. 选择性雌激素受体调节剂研究现状[J]. 药学实践与服务, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
引用本文: 丁浩, 杨帆, 蔡艺, 柴晓云, 吴秋业. 选择性雌激素受体调节剂研究现状[J]. 药学实践与服务, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
DING Hao, YANG Fan, CAI Yi, CHAI Xiaoyun, WU Qiuye. Research progress on the selective estrogen receptor modulators[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
Citation: DING Hao, YANG Fan, CAI Yi, CHAI Xiaoyun, WU Qiuye. Research progress on the selective estrogen receptor modulators[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001

选择性雌激素受体调节剂研究现状

doi: 10.3969/j.issn.1006-0111.2016.01.001

Research progress on the selective estrogen receptor modulators

  • 摘要: 乳腺癌已经成为危害女性健康的主要恶性肿瘤,选择性雌激素受体调节剂作为治疗乳腺癌的有效药物越来越受到人们的广泛关注。笔者对选择性雌激素受体调节剂的研究现状进行综述。
  • [1] Advani P, Moreno-Aspitia A. Current strategies for the prevention of breast cancer[J], Breast Cancer (Dove Med Press), 2014, 6: 59-71.
    [2] 郑 莹, 吴春晓, 吴 凡, 等. 中国女性乳腺癌死亡现况和发展趋势[J]. 中华预防医学杂志, 2011, 45(2): 150-154.
    [3] Fan L, Strasser-Weippl K, Li JJ, et al. Breast cancer in China[J]. Lancet Oncol, 2014, 15(7): 279-289.
    [4] Germain D. Estrogen carcinogenesis in breast cancer[J]. Endocrinol Metab Clin North Am, 2011, 40(3): 473-484.
    [5] Nelson ER, Wardell SE, McDonnell DP. The molecular mechanisms underlying the pharmacological actions of estrogens, SERMs and oxysterols: Implications for the treatment and prevention of osteoporosis[J]. Bone, 2013, 53(1): 42-50.
    [6] Ortona E, Pierdominici M, Berstein L. Autoantibodies to estrogen receptors and their involvement in autoimmune diseases and cancer[J]. J Steroid Biochem Mol Biol, 2014, 144: 260-267.
    [7] Osborne CK, Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications[J]. J Clin Oncol, 2005, 23: 1616-1622.
    [8] Mirkin S, Pickar JH. Selective estrogen receptor modulators (SERMs): A review of clinical data[J]. Maturitas, 2015, 53: 52-57.
    [9] Nagaraj G, Ma C. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer[J]. Breast Cancer Res Treat, 2015,150(2):231-242.
    [10] Shanle EK, Xu W. Endocrine disrupting chemicals targeting estrogen receptor signaling: identification and mechanisms of action[J]. Chem Res Toxicol, 2011, 24: 6-19.
    [11] Komm BS, Mirkin S. An overview of current and emerging SERMs[J]. J Steroid Biochem Mol Biol, 2014, 143:207-222.
    [12] Williams C, Lin CY. Oestrogen receptors in breast cancer: basic mechanisms and clinical implications[J]. Ecancermedicalscience, 2013, 7:370.
    [13] Hadji P. The evolution of selective estrogen receptor modulators in osteoporosis therapy[J]. Climacteric, 2012, 15 (6): 513-523.
    [14] Maximov PY, Lee TM, Jordan VC. The discovery and development of selective estrogen receptor modulators (SERMs) for clinical practice[J]. Curr Clin Pharmacol, 2013, 8(2): 135-155.
    [15] Jordan VC, McDaniel R, Agboke F, et al. The evolution of nonsteroidalantiestrogens to become selective estrogen receptor modulators[J]. Steroids, 2014, 90: 3-12.
    [16] Kaur G, Mahajan MP, Pandey MK. Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents[J]. Eur J Med Chem, 2014, 86: 211-218.
    [17] Silverman S, Christiansen C. Individualizing osteoporosis therapy[J]. Osteoporos Int, 2012, 23 (3): 797-809.
    [18] Gennari L, Merlotti D, Stolakis K, et al. Lasofoxifene, from the preclinicaldrug discovery to the treatment of postmenopausal osteoporosis[J]. Expert Opin Drug Discov, 2011, 6 (2): 205-217.
    [19] Michalsen BT, Gherezghiher TB, Choi J, et al. The selective estrogen receptor modulator (SERM) Lasofoxifeneformsreactive quinonessimilar to estradiol[J]. Chem Res Toxicol, 2012, 25(7) : 1472-1483.
    [20] Vessières A, Top S, Beck W, et al. Metal complex SERMs (selective estrogen receptor modulators). The influence of different metal units on breast cancer cell antiproliferativeeffects[J]. Dalton Trans, 2006, 4: 529-541.
    [21] Li M J, Greenblatt HM, Dym O, et al. Structure of estradiol metal chelate and estrogen receptor complex: The basis for designing a new class of selective estrogen receptor modulators[J]. J Med Chem, 2011, 54(10): 3575-3580.
    [22] Top S, Vessi res A, Leclercq G, et al. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines[J]. Chemistry, 2003, 9(21): 5223-5236.
    [23] Plazuk D, Vessi res A, Hillard EA, et al. A[3]ferrocenophane polyphenol showing a remarkable antiproliferative activity on breast and prostate cancer cell lines[J]. J Med Chem, 2009, 52(15): 4964-4967.
    [24] Jain N, Kanojia RM, Xu J, et al. Novelchromene-derived selective estrogen receptor modulators usefulfor alleviating hot flushes and vaginal dryness[J]. J Med Chem, 2006, 49(11): 3056-3059.
    [25] Jain N, Xu J, Kanojia RM, et al. Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms[J]. J Med Chem, 2009, 52: 7544-7569.
    [26] Paterni I, Granchi C, Katzenellenbogen JA, et al. Estrogen receptors alpha (ERα) and beta (ERβ): subtype-selectiveligands and clinicalpotential[J]. Steroids, 2014, 90: 13-29.
    [27] Kim S, Wu JY, Birzin ET, et al. Estrogen Receptor Ligands. II. Discovery of benzoxathiins as potent, selective estrogen receptorαmodulators[J]. J Med Chem, 2004, 47(9): 2171-2175.
    [28] Liao ZQ, Dong C, Carlson KE, et al. Triaryl-substitutedschiff bases are high-affinity subtype-selective ligands for the estrogenreceptor[J]. J Med Chem, 2014, 57: 3532-3545.
    [29] Carroll VM, Jeyakumar M, Carlson KE, et al. Diarylpropionitrile (DPN) enantiomers: synthesis and evaluation of estrogen receptor β-selective ligands[J]. J Med Chem, 2012, 55: 528-537.
    [30] Ohta K, Ogawa T, Kaise A, et al. Aliphatic substitution of ocarboranyl phenols enhances estrogen receptor beta selectivity[J]. Chem Pharm Bull, 2014, 62: 386-391.
  • [1] 唐淑慧, 凤美娟, 薛智霞, 鲁桂华.  帕博利珠单抗治疗所致免疫相关不良反应与中医体质的相关性研究 . 药学实践与服务, 2024, 42(5): 217-222. doi: 10.12206/j.issn.2097-2024.202311029
    [2] 张晶晶, 索丽娜, 郑兆红.  89例细菌性肝脓肿的临床特征及抗感染治疗分析 . 药学实践与服务, 2024, 42(6): 267-272. doi: 10.12206/j.issn.2097-2024.202302039
    [3] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202310044
    [4] 王耀振, 徐灿, 吕顺莉, 田泾, 张东炜.  钾离子竞争性酸阻滞剂的药学特征研究进展 . 药学实践与服务, 2024, 42(7): 278-284. doi: 10.12206/j.issn.2097-2024.202306040
    [5] 张艺昕, 关欣怡, 王博宁, 闻俊, 洪战英.  二氢吡啶类钙离子拮抗药物手性分析及其立体选择性药动学研究进展 . 药学实践与服务, 2024, 42(8): 1-6. doi: 10.12206/j.issn.2097-2024.202308062
  • 加载中
计量
  • 文章访问数:  3797
  • HTML全文浏览量:  336
  • PDF下载量:  139
  • 被引次数: 0
出版历程
  • 收稿日期:  2014-10-13
  • 修回日期:  2015-06-05

选择性雌激素受体调节剂研究现状

doi: 10.3969/j.issn.1006-0111.2016.01.001

摘要: 乳腺癌已经成为危害女性健康的主要恶性肿瘤,选择性雌激素受体调节剂作为治疗乳腺癌的有效药物越来越受到人们的广泛关注。笔者对选择性雌激素受体调节剂的研究现状进行综述。

English Abstract

丁浩, 杨帆, 蔡艺, 柴晓云, 吴秋业. 选择性雌激素受体调节剂研究现状[J]. 药学实践与服务, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
引用本文: 丁浩, 杨帆, 蔡艺, 柴晓云, 吴秋业. 选择性雌激素受体调节剂研究现状[J]. 药学实践与服务, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
DING Hao, YANG Fan, CAI Yi, CHAI Xiaoyun, WU Qiuye. Research progress on the selective estrogen receptor modulators[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
Citation: DING Hao, YANG Fan, CAI Yi, CHAI Xiaoyun, WU Qiuye. Research progress on the selective estrogen receptor modulators[J]. Journal of Pharmaceutical Practice and Service, 2016, 34(1): 1-4,55. doi: 10.3969/j.issn.1006-0111.2016.01.001
参考文献 (30)

目录

    /

    返回文章
    返回